Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...

Metastatic breast cancer market is projected to grow significantly through 2035, driven by rising cases, treatment advances, and expanding R&D investments.

CLEOPATRA randomly assigned patients with newly diagnosed advanced HER2-positive breast cancer to docetaxel and trastuzumab with ... the discovery of molecular drivers of disease biology and markers ...

The meeting of the American Society of Oncology focused on optimizing immunotherapy and other advanced treatments for ...

Triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer. Unlike ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

The phase 3 SERENA-6 trial shows that ctDNA-guided early treatment switch to camizestrant plus a CDK4/6 inhibitor in HR+, ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...